Merck is upgraded to buy, driven by improving dividend cushion ratio (DCR) and robust FQ4 2025 earnings recovery. Click here to read why MRK and ABBV.

Merck & Co. (NYSE:MRK) continues to lead in oncology and vaccines, with its financial strength and market presence shaping the S&P 500 Index.

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Merck & Co. Inc. (NYSE:MRK) is one of the best value stocks to buy now. On February 19, Merck announced positive second-season findings from the Phase 3 SMART trial evaluating ENFLONSIA (clesrovimab) ...

Stock futures slip after Trump tariff uncertainty. Watch Merck’s restructuring, Domino’s Q4 surge, Gilead’s Arcellx deal, and ...

Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc.

Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Merck & Co., Inc. (NYSE:MRK) with ...

Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can ...

Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, ...

As a constituent of leading indices including the Dow Jones Industrials Average Merck & Co., Inc. (NYSE:MRK) maintains visibility among large-cap healthcare peers. Index inclusion underscores its ...

Merck (MRK)’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a significant profit jump and heightened investor confidence. The factors behind this ...